Cargando…

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain

BACKGROUND: Cancer is a global public health problem, requiring efficient health system investments to deliver sustainable impact on population health. Access to medicines is a critical component of health systems, having a crucial role in delivering therapeutic benefits. Since 1977, the World Healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roitberg, F., Amaral, T., Cherny, N.I., Giuliani, R., Latino, N.J., Galotti, M., Bricalli, G., Curigliano, G., Pentheroudakis, G., Trapani, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594014/ https://www.ncbi.nlm.nih.gov/pubmed/37672862 http://dx.doi.org/10.1016/j.esmoop.2023.101617

Ejemplares similares

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience
por: Latino, N.J., et al.
Publicado: (2022)

Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines
por: Zarkavelis, G., et al.
Publicado: (2022)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

ESMO Designated Centres of Integrated Oncology and Palliative Care (ESMO DCs): education, research and programme development survey
por: Kreye, G., et al.
Publicado: (2022)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020)

Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process
por: Wolf, I., et al.
Publicado: (2022)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
por: Eniu, Alexandru, et al.
Publicado: (2019)

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
por: Pentheroudakis, G., et al.
Publicado: (2022)

ESMO and WHO: 14 years of working in partnership on cancer control
por: Ullrich, Andreas, et al.
Publicado: (2016)

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology
por: Castelo-Branco, L., et al.
Publicado: (2021)

COVID-19 vaccines in patients with cancer
por: Trapani, Dario, et al.
Publicado: (2021)

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021()
por: Trapani, Dario, et al.
Publicado: (2021)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

Comparing Lifestyle Modifications and the Magnitude of Their Associated Benefit on Cancer Mortality
por: Dougherty, Timothy P., et al.
Publicado: (2023)

Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’
por: Grössmann, N., et al.
Publicado: (2021)

Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments
por: Trapani, Dario, et al.
Publicado: (2022)

Distribution of the workforce involved in cancer care: a systematic review of the literature
por: Trapani, D., et al.
Publicado: (2021)

Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines
por: Eniu, Alexandru, et al.
Publicado: (2016)

Individual differences in working memory capacity are unrelated to the magnitudes of retrocue benefits
por: Ye, Chaoxiong, et al.
Publicado: (2021)

Two Orders of Magnitude Variation of Diffusion-Enhanced Förster Resonance Energy Transfer in Polypeptide Chains
por: Jacob, Maik H., et al.
Publicado: (2018)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic
por: Tarantino, Paolo, et al.
Publicado: (2020)

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
por: Trapani, Dario, et al.
Publicado: (2020)

Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next?
por: Gribben, John G., et al.
Publicado: (2020)

Incretin action on bone: An added benefit?
por: Ma, Ronald C W, et al.
Publicado: (2015)

Outcome Probability versus Magnitude: When Waiting Benefits One at the Cost of the Other
por: Young, Michael E., et al.
Publicado: (2014)

The magnitude of the survival benefit of internal thoracic artery grafting: Absolute risk reduction
por: Ohno, Takayuki
Publicado: (2021)

Association between control group therapy and magnitude of clinical benefit of cancer drugs
por: Molto, Consolacion, et al.
Publicado: (2022)

Quantifying geographical accessibility to cancer clinical trials in different income landscapes
por: Tini, G., et al.
Publicado: (2022)

Cognitive psychology in and out of the laboratory /
por: Galotti, Kathleen M., 1957-
Publicado: (2004)

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jdk2cechbfekr3t8ci13515h9u